News

BLU-554 is indicated to treat advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, while BLU-285 is for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST). The company noted that it is also

The trial showed that atezolizumab shrank tumors in people with locally advanced or metastatic urothelial bladder cancer (UBC) who had progressed on initial treatment. High amounts of Programmed

Around 66 patients will be enrolled in this open label, non-randomized Phase I trial, which is divided into a dose-escalation phase and an expansion cohort phase. The trial

Resunab is a new synthetic oral drug that is a preferential agonist to the CB2 receptor expressed on activated immune cells. The company noted that CB2 activation triggers

FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R) and it targets macrophages and monocytes, which are activated or elevated in multiple disease settings. Five Prime

The 250mg once daily tablets are approved for NSCLC patients whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as

Harnessing the patient’s immune system is a promising new avenue in the fight against cancer that continues to garner significant momentum and excitement. Turnstone’s technology platform, Marabex, is

Taptiqom is a preservative-free eye drop solution (in single dose containers) of a fixed dose combination of the prostaglandin analogue tafluprost (15 micrograms/ml) and the beta-blocker timolol (5

"We were looking for a partner who has a clinical trial system that manages clinical data and automates the data capture and laboratory processes in Phase I units,"